Development of the Composition and Technology for Obtaining Paclitaxel Nanoscale Formulation Consisting of a Conjugate of Polymer Particles with a Protein Vector Molecule

Тип документаJournal Article
Дата публикации2021-11-25
Название журналаDrug development & registration
ИздательCenter of Pharmaceutical Analytics Ltd
Квартиль по SCImagoQ3
Квартиль по Web of Science
Импакт-фактор 2021
ISSN23052066, 26585049
Drug Discovery
Pharmaceutical Science
Краткое описание

Introduction. The use of the anticancer drug paclitaxel is limited due to its high toxicity and lipophilicity. A new polymer composition of paclitaxel has been proposed, which provides targeted transport of the drug into tumor cells and improves its safety.

Aim. Method development for preparation of a novel paclitaxel formulation consisting of a conjugate of PLGA nanoparticles with the third domain of alpha-fetoprotein.

Materials and methods. The object of this study is paclitaxel-loaded nanoparticles based on a copolymer of lactic and glycolic acids, the surface of which is modified with a vector molecule - the recombinant third domain of alpha-fetoprotein. Nanoparticles were obtained by single emulsification method and precipitation. Conjugation with a protein molecule was performed by the carbodiimide method. The analysis of the obtained nanoparticles was carried out using dynamic and electrophoretic light scattering, high performance liquid chromatography, dialysis membrane method.

Results and discussion. Synthesis of paclitaxel-loaded nanoparticles based on a copolymer of lactic and glycolic acids and its conjugation optimization under varying a wide range of conditions have been carried out. The resulting conjugate had an average diameter of 280 ± 12 nm. The conjugation efficiency was 95 %. The release of paclitaxel from the polymer matrix in the release medium was 65 % in 220 h.

Conclusions. A method of obtaining and substantiating the composition of the original nanosized form of paclitaxel is proposed. The possibility of prolonged release of paclitaxel from the polymer matrix has been shown.

Пристатейные ссылки: 26
Цитируется в публикациях: 1
Validated HPLC method for paclitaxel determination in PLGA submicron particles conjugated with α-fetoprotein third domain: Sample preparation case study
Sokol M., Zenin V., Yabbarov N., Mollaev M., Zabolotsky A., Mollaeva M., Fomicheva M., Kuznetsov S., Popenko V., Seregina I., Nikolskaya E.
Q3 Annales Pharmaceutiques Francaises 2021 цитирований: 1
Type of pH sensitive linker reveals different time-dependent intracellular localization, in vitro and in vivo efficiency in alpha-fetoprotein receptor targeted doxorubicin conjugate
Mollaev M., Gorokhovets N., Nikolskaya E., Faustova M., Zabolotsky A., Zhunina O., Sokol M., Zamulaeva I., Severin E., Yabbarov N.
Q1 International Journal of Pharmaceutics 2019 цитирований: 12
Open Access
Open access
Formulation of perspective hepatoprotector polymeric forms based on silybin and ursodeoxycholic acid
Tereshchenko O.G., Nikolskaya E.D., Zhunina O.A., Zavarzina V.V., Yabbarov N.G., Fomicheva M.V., Zubkov E.V., Sokol M.B., Gukasova N.V., Severin E.S.
Q3 Russian Chemical Bulletin 2018 цитирований: 7
Resveratrol-loaded PLGA nanoparticles: enhanced stability, solubility and bioactivity of resveratrol for non-alcoholic fatty liver disease therapy
Wan S., Zhang L., Quan Y., Wei K.
Q1 Royal Society Open Science 2018 цитирований: 48
Open Access
Open access
Bare and Sterically Stabilized PLGA Nanoparticles for the Stabilization of Pickering Emulsions
Albert C., Huang N., Tsapis N., Geiger S., Rosilio V., Mekhloufi G., Chapron D., Robin B., Beladjine M., Nicolas V., Fattal E., Agnely F.
Q1 Langmuir 2018 цитирований: 16
Development of novel PLGA nanoparticles with co‐encapsulation of docetaxel and abiraterone acetate for a highly efficient delivery into tumor cells
Sokol M.B., Nikolskaya E.D., Yabbarov N.G., Zenin V.A., Faustova M.R., Belov A.V., Zhunina O.A., Mollaev M.D., Zabolotsky A.I., Tereshchenko O.G., Severin E.S.
Q2 Journal of Biomedical Materials Research - Part B Applied Biomaterials 2018 цитирований: 26
Harnessing albumin as a carrier for cancer therapies
Hoogenboezem E.N., Duvall C.L.
Q1 Advanced Drug Delivery Reviews 2018 цитирований: 149
Alpha-fetoprotein: A fabulous biomarker in hepatocellular, gastric and rectal cancer diagnosis
Naz Z., Usman S., Saleem K., Ahmed S., Bashir H., Bilal M., Sumrin A.
Q3 Biomedical Research 2018 цитирований: 12
The battle of “nano” paclitaxel
Sofias A.M., Dunne M., Storm G., Allen C.
Q1 Advanced Drug Delivery Reviews 2017 цитирований: 159
Investigation and optimization of formulation parameters on preparation of targeted anti-CD205 tailored PLGA nanoparticles
Haddadi A., Jahan S.T.
Q1 International Journal of Nanomedicine 2015 цитирований: 4
Open Access
Open access
Release Kinetics Study of Poorly Water-Soluble Drugs from Nanoparticles: Are We Doing It Right?
Abouelmagd S.A., Sun B., Chang A.C., Ku Y.J., Yeo Y.
Q1 Molecular Pharmaceutics 2015 цитирований: 109
Nanoprecipitation of polymers in a bad solvent
Lebouille J.G., Stepanyan R., Slot J.J., Cohen Stuart M.A., Tuinier R.
Q2 Colloids and Surfaces A: Physicochemical and Engineering Aspects 2014 цитирований: 34
Abraxane® versus Taxol® for patients with advanced breast cancer: A prospective time and motion analysis from a Chinese health care perspective
Dranitsaris G., Yu B., Wang L., Sun W., Zhou Y., King J., Kaura S., Zhang A., Yuan P.
Q3 Journal of Oncology Pharmacy Practice 2014 цитирований: 23
PLGA-based nanoparticles: An overview of biomedical applications
Danhier F., Ansorena E., Silva J.M., Coco R., Le Breton A., Préat V.
Q1 Journal of Controlled Release 2012 цитирований: 1934
Antitumor activity of targeted nanosome delivery systems based on poly(lactic-co-glycolic acid) nanoparticles, paclitaxel, and a recombinant alpha-fetoprotein fragment
Godovannyi A.V., Vorontsov E.A., Gukasova N.V., Pozdnyakova N.V., Vasilenko E.A., Yabbarov N.G., Severin S.E., Severin E.S., Gnuchev N.V.
Q4 Nanotechnologies in Russia 2012 цитирований: 6
Метрики
Поделиться
Цитировать
ГОСТ |
Цитировать
1. Sokol M.B. и др. Development of the Composition and Technology for Obtaining Paclitaxel Nanoscale Formulation Consisting of a Conjugate of Polymer Particles with a Protein Vector Molecule // Drug development & registration. 2021. Т. 10. № 4. С. 81–88.
RIS |
Цитировать

TY - JOUR

DO - 10.33380/2305-2066-2021-10-4-81-88

UR - http://dx.doi.org/10.33380/2305-2066-2021-10-4-81-88

TI - Development of the Composition and Technology for Obtaining Paclitaxel Nanoscale Formulation Consisting of a Conjugate of Polymer Particles with a Protein Vector Molecule

T2 - Drug development & registration

AU - Sokol, M. B.

AU - Yabbarov, N. G.

AU - Mollaeva, M. R.

AU - Chirkina (Fomicheva), M. V.

AU - Balaban'yan, V. Yu.

AU - Nikolskaya, E. D.

PY - 2021

DA - 2021/11/25

PB - Center of Pharmaceutical Analytics Ltd

SP - 81-88

IS - 4

VL - 10

SN - 2658-5049

SN - 2305-2066

ER -

BibTex |
Цитировать

@article{Sokol_2021,

doi = {10.33380/2305-2066-2021-10-4-81-88},

url = {https://doi.org/10.33380%2F2305-2066-2021-10-4-81-88},

year = 2021,

month = {nov},

publisher = {Center of Pharmaceutical Analytics Ltd},

volume = {10},

number = {4},

pages = {81--88},

author = {M. B. Sokol and N. G. Yabbarov and M. R. Mollaeva and M. V. Chirkina (Fomicheva) and V. Yu. Balaban{\textquotesingle}yan and E. D. Nikolskaya},

title = {Development of the Composition and Technology for Obtaining Paclitaxel Nanoscale Formulation Consisting of a Conjugate of Polymer Particles with a Protein Vector Molecule},

journal = {Drug development {\&} registration}

}

MLA
Цитировать
Sokol, M. B. et al. “Development of the Composition and Technology for Obtaining Paclitaxel Nanoscale Formulation Consisting of a Conjugate of Polymer Particles with a Protein Vector Molecule.” Drug development & registration 10.4 (2021): 81–88. Crossref. Web.